FDA Approves DATROWAY® for Advanced HR+/HER2- Breast Cancer
Trop-2-directed antibody-drug conjugateA new breast cancer treatment option
The United States Food and Drug Administration (FDA) approved DATROWAY® (datopotamab deruxtecan-dlnk) on January 17, 2025, for adults with hormone receptor-positive (HR+), HER2-negative breast cancer that is unresectable or metastatic and has already been treated with both endocrine therapy and chemotherapy.
What is DATROWAY?
DATROWAY is a Trop-2-directed antibody-drug conjugate that delivers a chemotherapy payload directly to cancer cells. It was developed by Daiichi Sankyo, Inc.
Administration
DATROWAY is administered via IV infusion once every 3 weeks.
Clinical Trial Snapshot
- Trial Name: TROPION-Breast01
- Patients: 732 (across 20 countries; 59 from the U.S.)
- Design: Compared DATROWAY vs. chemotherapy
- Key Results:
- Progression-Free Survival (PFS):
- DATROWAY: 6.9 months
- Chemotherapy: 4.9 months
- Also showed improved response rates and duration of response.
Potential Side Effects
DATROWAY may cause:
- Severe lung problems, including life-threatening or fatal interstitial lung disease (ILD)
- Mouth sores, eye irritation, keratitis
- Risk to unborn babies
Most common side effects include:
- Mouth ulcers, nausea, fatigue
- Low white/red blood cell counts, hair loss
- Constipation, dry eyes, liver enzyme elevation
Summary
DATROWAY offers a new treatment option for patients with difficult-to-treat HR+/HER2- breast cancer, showing better cancer control than standard chemo — but it carries significant risks that must be carefully managed.
Editor’s Note: This is another in our series of potentially game-changing novel pharmaceuticals that FDA approved in 2024 and 2025. This approval report does not in any way recommend or promote this product. For more information contact your oncologist or the manufacturer. Report any adverse effects experienced with this product to FDA’s Medwatch System.
Regulatory Documentation for National and Global Market Access
With a solid base of technical documentation, our regulatory specialists will prepare a regulatory submission that is organized, well written, complete, and meets the regulatory requirements of the agency that will evaluate the product.
FDA Information – Conveniently Organized and Accessible
Quickly find the FDA information you need Conveniently organized FDA information. The U.S. Food and Drug Administration (FDA) provides a wealth of information for consumers and industry stakeholders. The problem is, it can be difficult to navigate to the information...
Hospira Recalls Antibiotic for Presence of Glass Particles
Hospira, Inc., a division of Pfizer, announced a Class I recall of its Vancomycin Injection product due to visible glass particles that were identified in one vial of the drug. The recall involves lot 33045BA of Vancomycin Hydrochloride Injection USP 1.5g single dose...